Appili Therapeutics Inc Class A (TSE:APLI)
TSX:APLI
APLI Stock Chart & Stats
C$0.02
>-C$0.01(-14.29%)
At close: 4:00 PM EST
C$0.02
>-C$0.01(-14.29%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.04
Previous CloseN/A
Volume36.33K
Average Volume (3M)72.91K
Market Cap
C$2.57M
Enterprise ValueC$14.82M
Total Cash (Recent Filing)C$212.75K
Total Debt (Recent Filing)C$12.46M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding128,366,120
10 Day Avg. Volume40,186
30 Day Avg. Volume72,908
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.39
Price to Sales (P/S)5.13
P/FCF Ratio-1.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Infectious-disease PipelineAppili’s concentrated clinical-stage focus on antibacterial, antiviral and antifungal candidates creates a durable strategic niche. A clear pipeline (ATI-2307, ATI-1501) supports milestone-driven value creation, enhances partner appeal and aligns with persistent public-health demand over months.
Strong Reported Revenue Growth RateA reported ~72% revenue growth rate indicates improving top-line momentum versus prior periods. Given the clinical-stage context, sustained percentage growth—even from a low base—reflects program advancement or funded activity that can persist and de-risk near-term program milestones over 2–6 months.
Improving Cash-flow TrendTTM operating and free cash flow moved to only slightly negative (~-$0.02M), an improvement from prior larger burns. A trend toward near-breakeven cash flow lessens immediate dilution pressure, extends runway and provides a more stable base for executing clinical programs or securing partnerships.
Bears Say
Negative Shareholders' Equity And Thin Balance SheetThe balance sheet shows negative shareholders’ equity and sizable debt (~$12.5M) against very small total assets, creating a structurally thin capital base. This materially limits financial flexibility, raises refinancing risk and constrains the company’s ability to fund clinical development without external financing.
Persistent Operating LossesTTM net income is deeply negative (~-$3.0M) with sustained operating losses and sharply negative margins. Continued unprofitability undermines self-funding, restricts reinvestment into programs, and increases dependence on external capital, which can delay or dilute long-term value realization.
Reliance On External Funding Over Product SalesAs a pre-commercial biotech, Appili depends on grants, collaborations and capital markets rather than recurring product revenues. This structural funding model increases uncertainty around sustainable cash inflows, raises dilution and ties program progress to third-party contracts and partner timelines.
Appili Therapeutics Inc Class A News
APLI FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is C$2.57M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Jul 01, 2026 which is in 86 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Feb 12, 2026. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 128,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in TSE:APLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.